Skip to main content
Premium Trial:

Request an Annual Quote

Merrimack Raises $77M in Private Financing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Merrimack Pharmaceuticals this week said that it has raised $77 million in a Series G private financing.

The firm, which is developing cancer therapeutics and companion molecular diagnostics, said that it would use the funds to support its pipeline of cancer therapeutics.

Investors in the round included Credit Suisse First Boston Next Fund, Crocker Ventures, funds advised by Fred Alger Management, funds advised by Noonday Asset Management, Jennison Associates, TPG-Axon Capital, and WT Investment Advisors Fund.

Cambridge, Mass.-based Merrimack is using its own systems biology platform to discover and develop new drugs and molecular diagnostics.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.